title: Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC.
abstract: Lung cancer is the leading cause of cancer death in the US with ∼124,000 new cases annually, and a 5 y survival rate of ∼16%. Mutant KRAS-driven lung adenocarcinoma (KRAS LADC) is a particularly prevalent and deadly form of lung cancer. Protein kinase Cι (PKCι) is an oncogenic effector of KRAS that activates multiple signaling pathways that stimulate transformed growth and invasion, and maintain a KRAS LADC tumor-initiating cell (TIC) phenotype. PKCι inhibitors used alone and in strategic combination show promise as new therapeutic approaches to treatment of KRAS LADC. These novel drug combinations may improve clinical management of KRAS LADC.
authors.affiliation: a Department of Cancer Biology , Mayo Clinic , Jacksonville , FL , USA.
authors.forename: Alan P
authors.initials: AP
authors.lastname: Fields
authors.affiliation: a Department of Cancer Biology , Mayo Clinic , Jacksonville , FL , USA.
authors.forename: Syed A
authors.initials: SA
authors.lastname: Ali
authors.affiliation: a Department of Cancer Biology , Mayo Clinic , Jacksonville , FL , USA.
authors.forename: Verline
authors.initials: V
authors.lastname: Justilien
authors.affiliation: a Department of Cancer Biology , Mayo Clinic , Jacksonville , FL , USA.
authors.forename: Nicole R
authors.initials: NR
authors.lastname: Murray
mesh_terms: D000072283:A549 Cells; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology; D045744:Cell Line, Tumor; D006052:Gold Sodium Thiomalate / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D051379:Mice; D009154:Mutation; D014411:Neoplastic Stem Cells / Q000187:drug effects; D011493:Protein Kinase C / Q000378:metabolism*; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics*; D020123:Sirolimus / Q000008:administration & dosage* / Q000494:pharmacology; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays; D000099293:Protein Kinase C-lambda
chemical_list: D006052:Gold Sodium Thiomalate; D007527:Isoenzymes; D011493:Protein Kinase C; D016283:Proto-Oncogene Proteins p21(ras); D020123:Sirolimus; D000099293:Protein Kinase C-lambda; C117307:KRAS protein, human
keywords: Protein Kinase Ciota; lung adenocarcinoma; oncogenic Kras; therapeutic targeting